DXCM calls FDA label expansion of continuous-glucose monitor a “new era in diabetes management”: http://finance.yahoo.com/news/fda-approval-dexcom-non-adjunctive-210100548.html The stock was up 0.08%, so investors evidently think the new era won’t be that different from the old era.